WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis

European Journal of Cancer

Volumn 46, Issue 4, 2010, Pages 818-825

  Paige, Adam J W ^a   Zucknick, Manuela ^b,h   Janczar, Szymon ^a   Paul, Jim ^c   Mein, Charles A ^d   Taylor, Karen J ^e   Stewart, Moira ^e   Gourley, Charlie ^e   Richardson, Sylvia ^b   Perren, Timothy ^f   Ganesan, Trivadi S ^g   Smyth, John F ^e   Brown, Robert ^a   Gabra, Hani ^a  

^a Ovarian cancer action (HHMT) Research Centre   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Ovarian cancer; Single nucleotide polymorphism; Tumour modifier gene; Tumour suppressor gene; WWOX

Indexed keywords

GENOMIC DNA; PROTEIN P53; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE FREQUENCY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; WWOX GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OXIDOREDUCTASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 76249122288     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.021     Document Type: Article

References (30)

1. Smith D.I., McAvoy S., Zhu Y., and Perez D.S. Large common fragile site genes and cancer. Semin Cancer Biol 17 (2007) 31-41
2. McAvoy S., Ganapathiraju S.C., Ducharme-Smith A.L., et al. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res 118 (2007) 260-269
3. Aqeilan R.I., Trapasso F., Hussain S., et al. Targeted deletion of WWOX reveals a tumor suppressor function. Proc Natl Acad Sci USA 104 (2007) 3949-3954
4. Fujishita T., Doi Y., Sonoshita M., et al. Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice. Br J Cancer 91 (2004) 1571-1574
5. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61 (2001) 8068-8073
6. Fabbri M., Iliopoulos D., Trapasso F., et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102 (2005) 15611-15616
7. Gourley C., Paige A.J., Taylor K.J., et al. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 69 (2009) 4835-4842
8. Chang N.S., Pratt N., Heath J., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 276 (2001) 3361-3370
9. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., and Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60 (2000) 2140-2145
10. Paige A.J.W., Taylor K.J., Taylor C., et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98 (2001) 11417-11422
11. Iliopoulos D., Guler G., Han S.Y., et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24 (2005) 1625-1633
12. Wei S.H., Balch C., Paik H.H., et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12 (2006) 2788-2794
13. Gourley C., Paige A.J.W., Taylor K.J., et al. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 26 (2005) 1681-1689
14. Nunez M.I., Rosen D.G., Ludes-Meyers J.H., et al. W.W.O.X. protein expression varies among ovarian carcinoma histotypes, correlates with less favorable outcome. BMC Cancer 5 (2005) 64
15. Garg R., Wollan M., Galic V., et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol 103 (2006) 793-796
16. Yarden R.I., Friedman E., Metsuyanim S., Olender T., Ben-Asher E., and Papa M.Z. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111 (2008) 497-504
17. Lange E.M., Beebe-Dimmer J.L., Ray A.M., et al. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate 69 (2009) 385-391
18. Murabito J.M., Rosenberg C.L., Finger D., et al. A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet 8 Suppl. 1 (2007) S6
19. Marsh S., Paul J., King C.R., et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25 (2007) 4528-4535
20. Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 (2004) 1682-1691
21. Grambsch P., and Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515-526
22. Therneau T., Grambsch P., and Fleming T. Martingale based residuals for survival models. Biometrika 77 (1990) 147-160
23. van Buuren S., Boshuizen H.C., and Knook D.L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18 (1999) 681-694
24. van Buuren S, Oudshoorn K. Flexible multivariate imputation by MICE. Leiden; 1999.
25. Donati V., Fontanini G., Dell'Omodarme M., et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 13 (2007) 884-891
26. Stranger B.E., Nica A.C., Forrest M.S., et al. Population genomics of human gene e2cression. Nat Genet 39 (2007) 1217-1224
27. Pennacchio L.A., Ahituv N., Moses A.M., et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature 444 (2006) 499-502
28. Lee J.C., Weissglas-Volkov D., Kyttala M., et al. WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am J Hum Genet 83 (2008) 180-192
29. Pearce C.L., Wu A.H., Gayther S.A., et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. Br J Cancer 98 (2008) 282-288
30. Ramus S.J., Vierkant R.A., Johnatty S.E., et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 123 (2008) 380-388